[
  {
    "ts": null,
    "headline": "Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?",
    "summary": "We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other cheapest stocks to buy on Robinhood. While the market has been on an upward trajectory for nearly two years now, the combination of seasonal […]",
    "url": "https://finnhub.io/api/news?id=cd4e95945bdcf179e3f9906436af39e7551f43cba4e9b4b54e815658355dae3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732792081,
      "headline": "Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?",
      "id": 131687459,
      "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other cheapest stocks to buy on Robinhood. While the market has been on an upward trajectory for nearly two years now, the combination of seasonal […]",
      "url": "https://finnhub.io/api/news?id=cd4e95945bdcf179e3f9906436af39e7551f43cba4e9b4b54e815658355dae3d"
    }
  },
  {
    "ts": null,
    "headline": "Eisai Co., Ltd. - LEQEMBI for the Treatment of Alzheimer's disease Launched in South Korea",
    "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody 'LEQEMBI' has been launched in South Korea.LEQEMBI...",
    "url": "https://finnhub.io/api/news?id=8a308fbb6aae702e22d5f3e7379f1f25830186bd3538e9b547a14c7bd2c385a2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732783065,
      "headline": "Eisai Co., Ltd. - LEQEMBI for the Treatment of Alzheimer's disease Launched in South Korea",
      "id": 131684561,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody 'LEQEMBI' has been launched in South Korea.LEQEMBI...",
      "url": "https://finnhub.io/api/news?id=8a308fbb6aae702e22d5f3e7379f1f25830186bd3538e9b547a14c7bd2c385a2"
    }
  },
  {
    "ts": null,
    "headline": "\"LEQEMBI®\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody \"LEQEMBI®\" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's diseas",
    "url": "https://finnhub.io/api/news?id=31e53fbd21e99cdbbbe84b2c8c3037de31b2eba7196f7dd9b137a788aed1f662",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732753860,
      "headline": "\"LEQEMBI®\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea",
      "id": 131676080,
      "image": "https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody \"LEQEMBI®\" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's diseas",
      "url": "https://finnhub.io/api/news?id=31e53fbd21e99cdbbbe84b2c8c3037de31b2eba7196f7dd9b137a788aed1f662"
    }
  }
]